(P094) Treatment Outcomes of Sinonasal Neuroendocrine Cancer: A Retrospective Review

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Sinonasal neuroendocrine tumors are a challenging group of diseases to manage, due to their rarity and heterogeneous natural histories. New multimodality strategies need to be explored to potentially enhance outcomes, especially in non-ONB histologies.

Priya Parikh, BA, Samir H. Patel, MD, Mauricio Gamez, MD, William Wong, MD, Michele Halyard, MD, Kelly Curtis, MD, Devyani Lal, MD; Department of Radiation Oncology, Department of Medical Oncology, Department of Otorhinolaryngology, Mayo Clinic Arizona

PURPOSE/OBJECTIVES: To report the treatment outcomes of patients with sinonasal neuroendocrine tumors who were treated with a combination of surgery, radiation therapy, and/or chemotherapy at the Mayo Clinic in Arizona.

MATERIALS AND METHODS: An institutional review board (IRB)-approved retrospective study of 27 patients treated at the Mayo Clinic from January 25, 1996 through November 6, 2013. Of these patients, 9 (33%) had olfactory neuroblastoma (ONB), 11 (41%) had sinonasal undifferentiated carcinoma (SNUC), 5 (19%) had small-cell carcinoma, and 2 (7%) had neuroendocrine carcinoma.

Of the 27 patients, 22 patients received a combination of surgery, radiation therapy, and/or chemotherapy: 9 (41%) underwent surgery plus adjuvant radiation, 8 (36%) underwent surgery plus adjuvant chemoradiation, 4 (18%) were treated with chemoradiation, and 1 (5%) had neoadjuvant chemotherapy followed by surgery and adjuvant radiation. Two patients were treated with surgery alone, one was treated with radiation therapy alone, and two were treated with chemotherapy alone. The median dose of radiation was 60 Gy (range: 42–66 Gy).

RESULTS: Median follow-up was 16.3 months (range: 3–315 mo). The 5-year actuarial overall survival (OS), distant metastasis–free survival (DMFS), and local control (LC) rates were 44%, 62%, and 51%, respectively. When comparing outcomes of ONB vs non-ONB histologies, 5-year OS was 56% vs 38% (P = .4), and 5-year LC was 67% vs 37%, respectively (P = .6). Specifically, SNUC patients had the worst 5-year OS of 25% and 5-year LC of 39%. Moreover, 50% of SNUC patients developed distant failure within 1 year. There were five regional recurrences in the neck-all in ONB patients. One of these five patients had a regional-only recurrence and did not receive elective radiation to the neck.

CONCLUSIONS: Sinonasal neuroendocrine tumors are a challenging group of diseases to manage, due to their rarity and heterogeneous natural histories. New multimodality strategies need to be explored to potentially enhance outcomes, especially in non-ONB histologies.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.